|Bid||1.0200 x 0|
|Ask||1.0700 x 0|
|Day's Range||1.0700 - 1.0700|
|52 Week Range||1.0400 - 1.4500|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for PIJ.MULearn more
Key Insights Significant control over Platinum Investment Management by retail investors implies that the general...
In this article, we discuss the 15 stocks Australian billionaire Kerr Neilson is selling. If you want to skip our analysis of Neilson’s history and investment philosophy, go directly to Australian Billionaire Kerr Neilson is Selling These 15 Stocks. Kerr Neilson is a billionaire investor who co-founded Platinum Asset Management with Andrew Clifford nearly 28 […]
Every investor in Platinum Investment Management Limited ( ASX:PTM ) should be aware of the most powerful shareholder...
We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed...
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measuresEuropean Commission decision on marketing authorization application (MAA) expected in approximately 60 days If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG) Breda, the Netherlands—June 24, 2022—argenx (Eur